Prédisposition génétique à la neutropénie liée au traitement chez les patients atteints de leucémie infantile

Acute lymphoblastic leukaemia (ALL) is the most common malignant tumour in childhood. Over the years, the treatment of ALL has improved considerably. Intensive chemotherapy administered during the treatment protocol is nevertheless associated with adverse drug reactions. One of the adverse reactions associated with several anti-leukemic drugs is severe neutropenia, leading to life-threatening infections or frequent treatment interruptions. Genetic factors could influence the risk of neutropenia by modulating the progression of the disease and/or the effects of drugs. In this project, an association study between neutropenia and infections in children with LAL (whether or not these complications or their frequency occur) and genotypes of genetic variants will be conducted. Data on neutropenia and infections will be collected through hospital databases and medical records. The identification of polymorphisms that can predict the progression of treatment complications can help in the development of individualized treatment strategies that reduce the risk of toxicity.Translated with www.DeepL.com/Translator (free version)

Faculty Supervisor:

Maja Krajinovic

Student:

Partner:

Université Paul Sabatier

Discipline:

Life Sciences

Sector:

Education

University:

Université de Montréal

Program: